CNS Pharmaceuticals Berubicin Trial is On Schedule to Commence in March 2021
Potentially pivotal study evaluating efficacy of Berubicin in the treatment of adult Glioblastoma Multiforme (GBM), one of the most aggressive types of brain cancer
News provided by
Share this article
(NASDAQ: CNSP) ( CNS or the Company ), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today indicated that the clinical program for Berubicin is on track to start enrolling patients in March 2021. CNS lead product candidate, Berubicin, is a novel anthracycline and the first anthracycline to cross the blood-brain barrier. It is in development for the treatment of a number of serious brain and CNS oncology indications.